Business Context and Reporting Period
This Form 8-K filing by GRI Bio, Inc. (GRI) is dated January 15, 2026. The Company is listed on the Nasdaq Capital Market and is classified as an Emerging Growth Company. The report addresses a specific regulatory event regarding the Company's continued listing status.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references a prior non-compliance determination based on the Company's Form 10-Q for the quarter ended September 30, 2025, which indicated the Company did not meet the Stockholders' Equity Requirement of at least $2.5 million.
Material Changes
On January 15, 2026, the Nasdaq Listing Qualifications Staff notified GRI Bio that it has conditionally regained compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires companies with a market value under $35 million and annual net income under $500,000 to maintain stockholders' equity of at least $2.5 million. This status reverses a previous notification of non-compliance issued on December 2, 2025.
Outlook, Risks, and Contingencies
The Company's continued listing remains contingent upon demonstrating compliance with the Stockholders' Equity Requirement in future Exchange Act reports. The filing explicitly states that if the Company fails to maintain this compliance in subsequent filings, its common stock may again be subject to delisting.
Investor Verification Checklist
- Verify the specific stockholders' equity figure reported in the most recent Form 10-Q or 10-K to confirm the basis for regained compliance.
- Monitor upcoming periodic reports to ensure the Company continues to meet the $2.5 million equity threshold.
- Review the December 2, 2025, Form 8-K for details on the initial non-compliance notice.
- Confirm the Company's current market capitalization and annual net income to ensure it remains subject to Rule 5550(b)(1).